T-CURX GmbH Partners with Kytopen for Advanced Cell Therapies
Kytopen has announced an exciting partnership with T-CURX GmbH, expanding its reach and influence into Europe. T-CURX, a biotech company known for developing personalized immunotherapies, is set to gain on-site access to Kytopen's advanced Flowfect Tx™ cellular engineering platform.
The Importance of Flowfect Tx™ Technology
A crucial factor in T-CURX’s decision to collaborate was the proven capability of the Flowfect Tx™ platform for Good Manufacturing Practice (GMP) manufacturing of engineered cells. This technology validates the production of engineered cells at both clinical and commercial scales, addressing the needs of modern cellular therapies.
The Flowfect Tx™ platform is designed to optimize the gene delivery process. It does so by balancing a myriad of parameters that ensure quality while maintaining a continuous flow system capable of processing large volumes swiftly. Within minutes, this technology can generate hundreds of billions of high-quality engineered cells, satisfying the rising demand for effective cell therapies.
Enhanced Collaboration for Cell Therapy Development
As part of this partnership, T-CURX will benefit from extensive proof of concept process development using Kytopen’s Flowfect™ technology. The agreement not only secures access to the Flowfect Tx™ platform but also includes dedicated support from Kytopen's specialized Field Applications Team. This collaboration positions T-CURX for a significant advantage as they navigate through optimization processes from initial testing to large-scale clinical and commercial manufacturing.
Statements from the Leaders
Michael Chiu, CEO of Kytopen, expressed enthusiasm over this partnership, seeing T-CURX as a standout collaborator in Germany. He emphasized the potential of Europe as a vital market that is increasingly focused on the development of sophisticated cell therapies aimed at combatting cancer, autoimmune diseases, and other significant health challenges. Kytopen remains committed to facilitating partnerships that speed up the delivery of life-saving treatments to patients globally.
Ulf Grawunder, the CEO of T-CURX, echoed this excitement, highlighting the prospect of utilizing Kytopen’s GMP-validated Flowfect Tx™ platform. This collaboration is aligned with T-CURX’s mission to democratize CAR-T therapies by making them more affordable and accessible for a broader range of patients.
About Kytopen and T-CURX GmbH
Kytopen stands at the forefront of non-viral, continuous flow cellular engineering technologies. Based in Cambridge, Massachusetts, Kytopen focuses on maximizing cell therapy yields by producing engineered cells faster than any other technology available today. Their innovative processes not only enhance the production of cell therapies but also facilitate the broader goals of discovery and development of advanced engineered cellular therapies.
T-CURX GmbH is a biopharmaceutical company that dedicates its efforts to the development of next-generation CAR-T cell therapies to address serious medical needs in cancer treatment. With innovative technologies rooted in rigorous research, T-CURX aims to transform the landscape of CAR-T therapies, ensuring that these groundbreaking treatments are both effective and accessible.
Frequently Asked Questions
What is the significance of the partnership between T-CURX and Kytopen?
This collaboration allows T-CURX access to Kytopen's Flowfect Tx™ technology, enhancing its CAR-T cell therapy capabilities and production efficiency.
How does the Flowfect Tx™ platform benefit T-CURX?
The Flowfect Tx™ platform validates the GMP manufacturing process, enabling T-CURX to produce high-quality engineered cells rapidly and efficiently.
What are the goals of T-CURX in this collaboration?
T-CURX aims to upscale CAR-T manufacturing, making it more efficient and affordable, thereby broadening access to these vital therapies.
Where is Kytopen located?
Kytopen is headquartered in Cambridge, Massachusetts, known for its advanced biotechnological research and innovations.
What type of therapies does T-CURX focus on developing?
T-CURX specializes in CAR-T cell therapies targeted towards treating cancers, specifically those with high medical needs.
